UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
the
month of November 2008
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x
Form 40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Incorporation
by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated November 18,
2008 is hereby incorporated by reference into the registration statements on
Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055)
filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
on March 23, 2007 , October 30, 2007 and August 15, 2008, respectively, and
the
registration statements on Form S-8 (File No. 333-148058, File No. 333-148574
and File No. 333-154795)
filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
on December 14, 2007, January 18, 2008, and October 28, 2008,
respectively.
XTL
Biopharmaceuticals Announces Top-line results from the Bicifadine Phase 2b
Study
for Diabetic Neuropathic Pain
Study
failed to meet its primary endpoint
Valley
Cottage, New York, November 18, 2008 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) announced today the top-line
results from the Bicifadine Phase 2b clinical trial for the treatment of
diabetic neuropathic pain. The trial’s primary objective was to compare the
efficacy of two doses of Bicifadine against placebo in reducing pain associated
with diabetic neuropathy. The primary endpoint of the study was the reduction
in
pain score during the course of treatment. The company announced that the study
failed to meet its primary endpoint. The trial also failed to meet key secondary
analysis.
Ron
Bentsur, CEO of the company, commented: “We are all very disappointed with the
results of the study. We will devote the next few days to further analyze the
data and decide on the appropriate course of action for the Bicifadine program,
and for the company.”
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
||
|
Date:
November 18, 2008
|
By:
|
/s/
Ron Bentsur
|
|
Ron
Bentsur
|
||
|
Chief
Executive Officer
|
||